Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PCNA | P12004 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10938101 | 1.00 | SLC7A5 (0.46) | SLC7A5PCNAPPARGPPARAMEN1 | |
| SCHEMBL169322 | 0.91 | SLC7A5 (0.55) | SLC7A5ESR1ESR2 | |
| SCHEMBL169321 | 0.91 | SLC7A5 (0.55) | SLC7A5ESR1ESR2 | |
| Methane SCHEMBL17267562 | 0.89 | SLC7A5 (0.53) | SLC7A5ESR1ESR2 | |
| SCHEMBL11198590 | 0.88 | SLC7A5 (0.47) | SLC7A5PCNAPPARGPPARAMEN1 | |
| SCHEMBL30716564 | 0.88 | PCNA (0.44) | SLC7A5PCNAPPARGPPARAMEN1 | |
| SCHEMBL11198579 | 0.88 | SLC7A5 (0.47) | SLC7A5PCNAPPARGPPARAMEN1 | |
| SCHEMBL17845882 | 0.87 | PCNA (0.37) | SLC7A5PCNAPPARGPPARALDHA | |
| SCHEMBL7276725 | 0.85 | SLC7A5 (0.46) | SLC7A5PCNAPPARGPPARAMEN1 | |
| SCHEMBL31409225 | 0.84 | ESR1 (0.51) | PCNAMEN1KMT2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4684002-A2 | THYROCYTES AND USES THEREOF | Lifenet Health (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250345488-A1 | CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-11-13 | — | — | US | claimed |
| CN-120121693-A | Identification of thyroid hormones using reactive heterogeneous nanopores | 南京大学 | 2025-06-10 | — | — | CN | claimed |
| WO-2024197069-A2 | THYROCYTES AND USES THEREOF | LIFENET HEALTH (US) | 2024-09-26 | — | — | WO | claimed |
| CN-116699150-A | Biosensing analysis method for detecting thyroid hormone binding activity in water sample | 清华大学 | 2023-09-05 | — | — | CN | claimed |
| CN-114609265-A | Method for detecting eight thyroid hormone markers in serum by liquid chromatography tandem mass spectrometry technology | 徐州医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114609266-A | Application of marker in preparation of diagnostic reagent for thyroid related diseases | 徐州医科大学 | 2022-06-10 | — | — | CN | claimed |
| US-9890116-B2 | Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine | BRACCO IMAGING S.P.A. (IT) | 2018-02-13 | — | — | US | claimed |
| EP-2694471-B1 | PROCESS FOR THE PREPARATION OF A SULFATED DERIVATIVE OF 3,5-DIIODO-O-[3-IODOPHENYL]-L-TYROSINE | BRACCO IMAGING SPA (IT) | 2017-08-02 | — | — | EP | claimed |
| WO-2001035902-A9 | STABILIZED THYROXINE COMPOUNDS | LOTUS BIOCHEMICAL CORP (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001035902-A2 | STABILIZED THYROXINE COMPOUNDS | LOTUS BIOCHEMICAL CORPORATION (US) | 2001-05-25 | — | — | WO | claimed |
| WO-1996040048-A9 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | — | 1997-03-27 | — | — | WO | claimed |
| EP-0357725-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LUNG OBSTRUCTIONS | SMITH, Ulf Per Gustav (SE) | 1992-04-15 | — | — | EP | claimed |
| EP-0073865-B1 | DERIVATIVES OF IODOTHYRONINE COMPOUNDS AND THEIR USE IN AN ASSAY FOR THE FREE IODOTHYRONINE COMPOUNDS | AMERSHAM INTERNATIONAL plc (GB) | 1986-01-29 | — | — | EP | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
| US-4426453-A | Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds | AMERSHAM INTERNATIONAL LIMITED (GB) | 1984-01-17 | — | — | US | claimed |
| EP-0093653-A1 | Process for the preparation of iodo-thyronines and iodo-thyroacetic acids by electrochemical reduction at a controlled potential | SPIRAL Société à responsabilité limitée dite : (FR) | 1983-11-09 | — | — | EP | claimed |
| EP-0073865-A1 | Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds | AMERSHAM INTERNATIONAL plc (GB) | 1983-03-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | NPPA, MACF1, IGF1R | SLC7A5 654/4885PCNA 67/4885PPARG 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.